Dirty Ashtray and Exploding Vape Awards Given to Big Tobacco and Social Media

Aug.29.2023
Dirty Ashtray and Exploding Vape Awards Given to Big Tobacco and Social Media
BAT and Meta receive "Dirty Ashtray" and "Exploding e-cigarette" awards at an Australian ceremony for undermining tobacco control strategies.

British American Tobacco (BAT) and the American social media company Meta were both awarded at a ceremony held in Perth, Australia, on August 29. BAT received the "Dirty Ashtray Award" while Meta won the inaugural "Exploding e-cigarette" award. These annual awards are presented by the Australian Medical Association (AMA) and the Australian Council on Smoking and Health (ACOSH) to highlight industries and organizations that undermine tobacco and e-cigarette control strategies in Australia.


The British American Tobacco Company is a proponent of Responsible Vaping Australia (RVA), having received recognition for supporting and funding a campaign aimed at undermining Australia's public health policies regarding e-cigarettes.


Meta, the owner of Facebook, Instagram, Threads, and WhatsApp, has won an award for its failure to enforce its policy of banning the promotion of tobacco or nicotine products on its platforms.


Laura Hunter, CEO of the Australian Council on Smoking and Health (ACOSH), has stated that RVA is a front for British American Tobacco (BAT), as the company aims to sell e-cigarettes in the retail market.


Tobacco giant British American Tobacco pretended to be concerned about the rise of the black market for e-cigarettes and the increasing number of teenagers using e-cigarettes, using the cover of RVA. The company lobbied the government and enlisted various community departments and organizations, who may be unaware that the large tobacco company is the mastermind behind their lobbying efforts. Consequently, they have rightly earned the 2023 Ashtray Award.


The inaugural "Explosive E-cigarette Awards" revealed individuals who endorse and spread information about the tobacco industry. Meta holds unparalleled influence in the virtual world, with a significant impact.


Meta's website proudly displays a policy that clearly promises to prohibit e-cigarette advertising or promotions on its platform. However, a quick glance reveals that this promise has not been enforced.


Mrs. Hunter stated that the Meta platform is being utilized to facilitate the use and sale of e-cigarettes, making it easier for an increasingly younger audience to be exposed to these products.


The President of the American Medical Association, Professor Robeson, has announced that the government has implemented significant measures to ban nicotine e-cigarette products and restrict their usage to only those prescribed by doctors.


The presence of filthy ashtrays and explosive e-cigarette incidents underscores the need to address the unregulated advertising of nicotine products on social media and prevent tobacco industry participants from funding political and lobbying groups.


Professor Robson said, "In order to safeguard the health of all Australians, our colleagues in the health and tobacco control departments are in favor of the government's introduction of new tobacco and e-cigarette reforms.


Over a hundred representatives from the Australian Public Health Alliance, dedicated to reducing smoking and e-cigarette consumption, attended a breakfast meeting. Among them was Minister for Health and Aged Care, Mark Butler, who discussed the next steps in government tobacco control legislation.


References


The Dirty Ashtray and Exploding Vape awards were recently given to big tobacco companies and social media platforms.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | BAT Revises Japan's VELO Convenience Store Lineup, Adding ¥380 Mango Pouches as Selected SKUs Exit
Product | BAT Revises Japan's VELO Convenience Store Lineup, Adding ¥380 Mango Pouches as Selected SKUs Exit
British American Tobacco's Japanese subsidiary, BAT Japan, launched VELO Mango Ice Medium on November 2, 2026, with distribution expanding to selected 7-Eleven, FamilyMart, NewDays and Seicomart stores from November 3. The new oral tobacco product contains 15 pouches per can and retails for ¥380, featuring a mango and cooling flavor profile at Medium intensity. At the same time, BAT Japan raised prices on multiple existing VELO products from ¥360 to ¥380 per can and withdrew selected SKUs from convenience store distribution without discontinuing them entirely. The changes affect product assortment, pricing and retail channel allocation.
product
Nov.04
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus distributor H&S said the zero-nicotine, zero-tar NEO vaping line will begin rolling out across FamilyMart stores in Japan from September 14, 2026, excluding some locations. The DASH line will also be sold at selected FamilyMart stores in southern Kyushu and Okinawa. Snowplus simultaneously named Japanese rock band Kishidan as a brand ambassador, combining convenience-store distribution with a broader consumer marketing push in Japan.
Sep.15
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
The U.S. Food and Drug Administration (FDA) has named Jessica Zeller director of the Center for Tobacco Products' (CTP) Office of Compliance and Enforcement (OCE), effective November 1, 2026. Zeller, the office's inaugural deputy director, returns from medical device manufacturer Edwards Lifesciences with more than 20 years of regulatory and legal experience. The appointment follows CTP leadership changes and adjustments to tobacco regulation. Bret Koplow became permanent CTP director in September; the FDA revised enforcement priorities for unauthorized e-cigarettes and nicotine pouches in May and announced faster PMTA review procedures. On September 28, the agency said it would evaluate changes to the existing PMTA regulatory framework, including potential rulemaking to replace it.
FDA
Oct.20 by 2Firsts Perspectives
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech launched IKE 2.0 on September 28, initially targeting nicotine products with a platform that combines user identity verification, product authentication, configurable policy controls and data analytics. Products can be authenticated through direct device integration or NFC smart tags. IKE Tech was formed with participation from Ispire's Aspire North America, Berify and Chemular, with Ispire currently holding a 40% interest. Its age-verification component PMTA was accepted by the FDA in 2025 and remains under review. The company did not disclose customer names, commercial deployment volumes, pricing or revenue tied to IKE 2.0.
News
Sep.29 by 2Firsts Perspectives
Special Report | Russia Places Four JTI Businesses Under Temporary Management, a First for Tobacco Majors
Special Report | Russia Places Four JTI Businesses Under Temporary Management, a First for Tobacco Majors
Russia has placed shares in four Japan Tobacco International businesses under temporary management, the first such move involving a major global tobacco manufacturer, according to Interfax. JTI held 35.8% of Russia's tobacco market by volume in the first nine months of 2026. While British American Tobacco and Imperial Brands have exited Russia, Philip Morris International continues operating there. As the market changes and diplomatic efforts continue, could international tobacco companies that left Russia eventually return?
Nov.06
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22